Skip to content
Spinify Resources UK

Patients Discontinuing Slimming Injections Gain Back Weight at a Quadrupled Rate Than People Using Diet and Exercise

Image of pharmaceutical injection and weighing machine
Obesity treatment involves long-term strategies.

New research indicates that individuals who come off new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt conventional lifestyle plans.

Research printed in a prominent medical journal points out that while obese people often shed substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.

"People purchasing such treatments need to be aware of the risk of quick rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.

Such speed of recovery means a reversion to original weight within about one and a half years.

Weighing Therapies

The research, which examined 37 of trials involving thousands of patients, contrasted the results of the injectable medications with older methods.

The team emphasize that individuals who lose weight through dieting generally have a more gradual weight regain—approximately 0.1 kg a month—once they finish.

The Reason for the Fast Regain

Doctors propose the mode of action of the injections is key to understanding the amplified weight return.

These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.

"Artificially providing GLP-1 concentrations far above than normal may cause the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.

"Discontinuation of this hormone supplement results in appetite is uncontrolled, making overeating far more likely."

A Lifelong Condition?

Health authorities suggest the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.

A number of clinicians argue that, due to the significant potential of relapse, the treatment should be considered ongoing.

This opinion is supported by pharmaceutical companies, who note that the findings "highlight the persistent nature of obesity," comparing it to managing diseases like high blood pressure.

Patient Accounts

Users who have discontinued the jabs describe a powerful return of appetite.

"I experienced something flipping and you're instantly extremely hungry," recalled one woman.

This difficulty is worsened if users have not developed lasting dietary or behavioural modifications during treatment.

Growing Interest

Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.

  • Adoption is more common among females than men.
  • The middle-aged demographic shows the greatest level of interest.
  • A large proportion obtain the medications through private healthcare rather than public health services.

Finally, researchers emphasize that while these medications are effective agents for weight loss, they are not a magic solution and long-term success hinges on integrated lifestyle management.

DS
The writer

Donald Sims

A seasoned business strategist with over 15 years of experience helping UK startups and SMEs scale through innovative growth frameworks.

Spinify Resources UK

Type to search articles.